Content by Sino Biological

A better understanding of immune checkpoint signaling can help improve future checkpoint inhibitor therapeutic approaches. 

One-stop end-to-end solutions support researchers at all stages of CAR T-cell therapy development.

In this symposium, an expert panel will discuss how the latest organoid models help researchers discover and develop new drugs. 

This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing.

Having the right reagents and tools accelerates autoimmune disease research.

Choosing the right 3D culture components and validation steps helps researchers unlock accurate, reproducible, and relevant insights into cancer biology.

On February 18, 2025, Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for pre-exposure prophylaxis (PrEP).